Tamar Tadmor
YOU?
Author Swipe
View article: Virtual reality and hypnosis for symptom alleviation before bone marrow procedure
Virtual reality and hypnosis for symptom alleviation before bone marrow procedure Open
View article: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial Open
Introduction Current treatment for chronic lymphocytic leukemia (CLL) follows two seminal paradigms: continuous Bruton tyrosine kinase inhibitor (BTKi) therapy until progression and fixed-duration regimens combining BCL2 inhibitors with a …
View article: Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study Open
Background. Clinical trials have documented the efficacy of ibrutinib in combination with venetoclax in CLL. Indeed, Ibrutinib plus venetoclax (I+V) is the first all oral fixed duration treatment approved for treatment naive patients with …
View article: CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia
CD19 CAR T‐Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia Open
Richter transformation (RT) is a serious complication of chronic lymphocytic leukaemia (CLL), with poor outcomes. While CAR T‐cells have shown promise in large B‐cell lymphoma, their efficacy in RT remains unclear, and the role of allogene…
View article: Triple A Plus ( <scp>AAA</scp> <sup>+</sup> ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
Triple A Plus ( <span>AAA</span> <sup>+</sup> ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients Open
Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple‐A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC)…
View article: The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL Open
Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear. We analyzed patients treated with Ven-Obi in the CLL13 and CLL14 tr…
View article: Approach to Hairy-Cell Leukemia in the New Therapeutic Era with Special Emphasis on Age and Comorbidities
Approach to Hairy-Cell Leukemia in the New Therapeutic Era with Special Emphasis on Age and Comorbidities Open
Background: Hairy-cell leukemia (HCL) is a rare chronic hematologic malignancy, generally presenting with pancytopenia, relative lymphocytosis, monocytopenia, and splenomegaly. Diagnosis is based on typical bone marrow evaluation with the …
View article: Gender Disparities in Health‐Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality
Gender Disparities in Health‐Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality Open
In chronic lymphocytic leukemia (CLL), treatment initiation is deferred until clinical symptoms emerge, aiming to minimize treatment‐related burden and maintain health‐related quality‐of‐life (QoL). We examined gender differences in QoL am…
View article: <scp>CCR5</scp> predicts neurotoxicity in <scp>CAR</scp>‐T‐cell therapy
<span>CCR5</span> predicts neurotoxicity in <span>CAR</span>‐T‐cell therapy Open
Patients undergoing chimeric antigen receptor T (CAR T)-cell therapy are at risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS). We observed an upregulation of CCR5 and CCR2 expression in CD4+ T cells among pa…
View article: 70 | THE TRIPLE COMBINATION OF VENETOCLAX‐IBRUTINIB‐OBINUTUZUMAB PROLONGS PFS COMPARED TO VENETOCLAX‐CD20‐ANTIBODY COMBINATIONS AND CHEMOIMMUNOTHERAPY IN TREATMENT‐NAIVE CLL
70 | THE TRIPLE COMBINATION OF VENETOCLAX‐IBRUTINIB‐OBINUTUZUMAB PROLONGS PFS COMPARED TO VENETOCLAX‐CD20‐ANTIBODY COMBINATIONS AND CHEMOIMMUNOTHERAPY IN TREATMENT‐NAIVE CLL Open
View article: OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL
OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL Open
View article: 344 | SERUM β2‐ MICROGLOBULIN LEVELS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: AN UNRECOGNIZED PROGNOSTIC FACTOR
344 | SERUM β2‐ MICROGLOBULIN LEVELS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: AN UNRECOGNIZED PROGNOSTIC FACTOR Open
View article: 216 | EPCORITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL‐1
216 | EPCORITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE CLL‐1 Open
View article: <scp>CLLAF SCORE</scp>—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive <scp>CLL</scp> Patients Initiating First‐ and Second‐Generation <scp>BTK</scp> Inhibitor Therapy
<span>CLLAF SCORE</span>—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive <span>CLL</span> Patients Initiating First‐ and Second‐Generation <span>BTK</span> Inhibitor Therapy Open
Background One of the limiting toxicities of BTKi is the development of atrial fibrillation (AF), with an incidence of 3%–16%. Aim This study aimed to identify patients with chronic lymphocytic leukemia (CLL) starting both first‐ and secon…
View article: Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL Open
Novel small molecule inhibitors have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Indeed, BTK (BTKi) and BCL2 inhibitors (BCL2i) alone or in combination with each other or other compounds have proven superior to chem…
View article: Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice
Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice Open
Background/Objectives: Polycythemia vera (PV) is a chronic hematologic neoplasm commonly treated with hydroxyurea (HU). We utilized the advanced digitalized database of Maccabi Healthcare Services to retrospectively investigate the clinica…
View article: Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms Open
View article: Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment
Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment Open
Low levels of vitamin D are associated with a shorter time to first treatment (TTFT) and inferior overall survival in patients with chronic lymphocytic leukemia (CLL). But whether vitamin D supplement affects the clinical course of patient…
View article: Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia
Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia Open
Introduction: Preexposure prophylaxis with monoclonal antibodies (mAbs) was developed in addition to COVID-19 vaccine for immunocompromised and those with insufficient immune response, among them patients with CLL. Omicron variant and its …
View article: The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma
The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma Open
The Lymphocyte-Activation Protein 3 (LAG-3) inhibitory receptor is expressed on regulatory plasma cells (PCs). Micro-environmental cells that express LAG-3 were found to be increased during the progression of smoldering multiple myeloma (S…
View article: Timing of <scp>BNT162b2</scp> vaccine prior to <scp>COVID</scp>‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study
Timing of <span>BNT162b2</span> vaccine prior to <span>COVID</span>‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study Open
The COVID‐19 pandemic continues to pose challenges to the treatment of hemato‐oncology patients. Emergence of COVID‐19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studi…
View article: The evolving landscape of <scp>COVID</scp>‐19 and <scp>post‐COVID</scp> condition in patients with chronic lymphocytic leukemia: A study by <scp>ERIC</scp>, the <scp>European</scp> research initiative on <scp>CLL</scp>
The evolving landscape of <span>COVID</span>‐19 and <span>post‐COVID</span> condition in patients with chronic lymphocytic leukemia: A study by <span>ERIC</span>, the <span>European</span> research initiative on <span>CLL</span> Open
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high‐count monoclonal B …
View article: P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY
P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY Open
Background: The BCL-2 inhibitor venetoclax in combination with an anti-CD20 monoclonal antibody has demonstrated improved outcomes and manageable safety compared to chemo-immunotherapy in phase III clinical trials for chronic lymphocytic l…
View article: P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS. Open
Background: The treatment for Chronic Lymphocytic Leukemia (CLL) has undergone significant changes over the past two decades. Initially, chemotherapy was the primary treatment, it was later replaced by chemo-immunotherapy, and more recentl…
View article: P1208: TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA
P1208: TRANSCRIPTOMIC PROFILING OF B CELL STATES AND MICROENVIROMENTAL ECOSYSTEMS REFINES THE PROGNOSTIC CLASSIFICATION OF DIFFUSE LARGE B CELL LYMPHOMA Open
Topic: 20. Lymphoma Biology & Translational Research Background: Diffuse Large B-cell Lymphoma (DLBCL) is the most frequent aggressive lymphoma, originating either from the germinal-center (GCB) or post-germinal cells (ABC). Currently, res…
View article: S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY. Open
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still …
View article: P1532: CLINICAL OUTCOMES OF COVID-19 IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME (MF/SS)
P1532: CLINICAL OUTCOMES OF COVID-19 IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME (MF/SS) Open
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Between 2020 and 2022, COVID-19 affected more than 70% of the Israeli population. It is now well known that haemato-oncologic patients are more susceptible to …
View article: P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The rarity of PMLBCL has prevented the development of dedicated, powerful and validated prognostic systems. The International Prognostic Index (IPI) and its age-adjusted var…
View article: The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic
The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic Open
In this study, we aim to explore the outcomes of Covid‐19 infection in patients with Hairy cell leukemia (HCL). The cohort is based on data obtained from electronic medical records. It includes 218 consecutive patients diagnosed with HCL b…
View article: REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS
REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS Open
Background: Real-life studies of moderate size have shown satisfactory but less impressive results compared with the original R-da-EPOCH publication for PMLBCL. However, large studies are needed efficacy and toxicity of R-da-EPOCH, the use…